There is an ongoing need to develop prognostic biomarkers to improve the management of clear cell renal cell carcinoma (ccRCC).
To leverage enriched pathways in ccRCC to improve risk-stratification.
There is an ongoing need to develop prognostic biomarkers to improve the management of clear cell renal cell carcinoma (ccRCC).
To leverage enriched pathways in ccRCC to improve risk-stratification.